Spotlight: Single Treatment With MM120 (Lysergide) in Generalized Anxiety DisorderA Randomized Clinical Trial (Robinson, et al, 2025)

"findings consistent w/ 2 prior reports - use of naltrexone in KUDs at the dosage of 50 mg/day successfully helped patients achieve abstinence... naltrexone reduces antidepressant effects of ketamine, indicating overlap between opioid system & ketamine's NMDA receptor activity. "

"we show that both parous parents and their children may be uniquely vulnerable to psychedelic treatment during the postpartum period"

"Psychedelics, such as psilocybin, lysergic acid diethylamide (LSD), ketamine, and N,N-dimethyltryptamine (DMT), have captured the attention of scientists, artists, and seekers alike for their profound ability to alter consciousness and inspire creativity."

"These compounds have been shown to enable access to unconscious cognitive and emotional content, facilitate emotional release, and induce a temporary dissolution of ego boundaries—processes that may underpin significant and enduring therapeutic outcomes."

" Maintenance intravenous racemic ketamine therapy demonstrated significant, persistent, and broad efficacy for treatment-resistant depression ...Side effect burden was no greater in higher doses as compared with lower. "

"To accommodate mainstream adoption of these treatments, the competencies framework we present respects the distinctive contextual and cultural sensitivities of psychedelic care while remaining anchored in established psychotherapeutic, medical, and scientific paradigms."